Key Drivers
- Strong ROIC/ROE
- Thin net margin
- High valuation multiples
AIAI Summary
GRDN has shifted from a thin-margin distributor to a cash-generative, margin-driven story where the investment case now hinges on repeatable adjusted-EBITDA beats and tighter working-capital management to justify its rich multiple. Near-term risk is elevated from a large insider-led secondary that increases float and could pressure the stock, so remain selective/watch until quarter-over-quarter margin improvement and demonstrable reduction in insider selling occur.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong ROIC/ROE
- •Thin net margin
- •High valuation multiples
GRDN is a cash-generative, high-ROIC business with strong free cash flow but thin net margins, moderate leverage, heavy working-capital needs, and rich valuation that raises downside risk.
Price Behavior
Key Price Behavior Insights:
- •Short-term uptrend
- •Extended above SMA
- •Near-term resistance
GRDN is in a short-term uptrend over the last month, rising from $33.54 to $35.62 (+≈6.2%) but is about 6.4% above the last-month 21-day SMA (~$33.50), suggesting it's extended and vulnerable to a pullback unless it holds above $35.62.
Price ~6.4% above last-month
Sentiment & News
Key News Insights:
- •Earnings beat
- •Raised guidance
- •Upsized secondary
Guardian Pharmacy beat Q4 expectations (EPS $0.37 vs $0.27) with 17% revenue growth, raised FY26 adjusted EBITDA guidance, saw residents served up 10%, and promptly completed an upsized 6M‑share secondary at $31 largely sold by existing holders.
Positive operational momentum and upgraded guidance support the stock's outlook, though the large secondary—primarily seller-led—may temper near-term share-price upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings